Industry News
Pharmaceutical Industry News
Community oncology is redefining…
Community oncology is redefining cancer care—advancing innovation, expanding trial access and keeping high-quality treatment close to home.
The new proposed board members…
The new proposed board members come after an extraordinary general meeting last fall saw a significant change in leadership.
Gilead penned a potential $1.5…
Gilead penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end a one-year-plus biotech IPO drought in Tokyo. Novo Nordisk faces increased GLP-1 competition in China. And
After the pharmaceutical industry…
After the pharmaceutical industry spent much of the past year safeguarding its businesses against the threat of U.S. import tariffs, a new Supreme Court ruling now waylays the Trump administration's trade agenda—at least in part.
AstraZeneca has secured a key…
AstraZeneca has secured a key regulatory win in its effort to reclaim the lead in the BTK inhibitor market, with the FDA approving its Calquence plus Venclexta as the first all-oral, fixed-duration regimen for first-line
After manufacturing the antibiotic…
After manufacturing the antibiotic Rocephin for four decades—and developing it into one of the company’s first blockbuster medicines—Roche is looking to divest the treatment and its production facility near its headquarters in Switzerland.
Novartis will transfer its 70.68%…
Novartis will transfer its 70.68% stake in Novartis India Limited—a Bombay Stock Exchange-listed company that primarily handles older and off-patent drugs in areas like immunology, neuroscience and pain—to a group of private equity firms.
As recent changes to U.S. vaccine…
As recent changes to U.S. vaccine policy face pushback on several fronts, one of the key bodies driving the nation's immunization recommendations is postponing its meeting previously planned for next week.
Throughout 2025, the world’s first…
Throughout 2025, the world's first metabolic dysfunction-associated steatohepatitis (MASH) drug generated just shy of a billion dollars. But Madrigal has much more growth in mind for the years to come.
In a fourth-quarter conference…
In a fourth-quarter conference call, Insmed CEO Will Lewis admitted that it was “audacious” that his company would project sales of newly approved respiratory drug Brinsupri to reach $1 billion in 2026. Then he laid
An untitled letter shared to the…
An untitled letter shared to the agency’s public database this month homes in on certain details of a commercial touting Tremfya’s use in ulcerative colitis.
As Enflonsia approaches the…
As Enflonsia approaches the one-year anniversary of its approval, Merck is padding the case for a label expansion that could see the protective antibody better match Sanofi and AstraZeneca’s rival infant RSV preventive Beyfortus.
Synthetic biology specialist Manus…
Synthetic biology specialist Manus Bio has scored a $15 million contract from the U.S. government to create a domestic supply source for shikimic acid, a key starting material used in the production of influenza drug
F.D.A. Reverses Decision and Agrees to Review Moderna’s Flu Vaccine
Moderna held further discussions with regulators and announced that the agency would accept the company’s application for approval of its flu vaccine that uses mRNA technology.
Kennedy’s MAHA Coalition Is a Mess
A political movement cannot survive on spite alone.
With an eye—and ear—toward…
With an eye—and ear—toward spreading the perseverance and optimism ingrained in the field of science, AbbVie has launched a new podcast series touting the work of its own scientists and other experts.
As President Donald Trump attempts…
As President Donald Trump attempts to convince Congress to write his Most Favored Nation drug pricing plan into law, he has received pushback from free-market conservatives. An interview with former Biden administration advisor John Barkett
In what will be the industry’s…
In what will be the industry’s most competitively contested market, FENIX power ranks the Top 10 obesity players positioned to outperform
GRAM’s CEO on specialization,…
GRAM’s CEO on specialization, re-shoring and rising demand in sterile fill manufacturing.
With $55 billion earmarked to…
With $55 billion earmarked to bolster its U.S. operations, Johnson & Johnson is the latest drugmaker to zero in on expansion plans that are aimed, at least in part, at abating the Trump administration’s pharmaceutical